- Home
- PHIO vs ABP Comparison
PHIO vs ABP Comparison
Compare PHIO & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHIO
- ABP
- Stock Information
- Founded
- PHIO 2011
- ABP 2004
- Country
- PHIO United States
- ABP United States
- Employees
- PHIO N/A
- ABP N/A
- Industry
- PHIO Biotechnology: Pharmaceutical Preparations
- ABP Biotechnology: Pharmaceutical Preparations
- Sector
- PHIO Health Care
- ABP Health Care
- Exchange
- PHIO Nasdaq
- ABP Nasdaq
- Market Cap
- PHIO 11.9M
- ABP 12.3M
- IPO Year
- PHIO N/A
- ABP N/A
- Fundamental
- Price
- PHIO $2.51
- ABP $0.27
- Analyst Decision
- PHIO Strong Buy
- ABP Strong Buy
- Analyst Count
- PHIO 2
- ABP 1
- Target Price
- PHIO $9.00
- ABP $4.00
- AVG Volume (30 Days)
- PHIO 118.9K
- ABP 12.7M
- Earning Date
- PHIO 08-13-2025
- ABP 08-18-2025
- Dividend Yield
- PHIO N/A
- ABP N/A
- EPS Growth
- PHIO N/A
- ABP N/A
- EPS
- PHIO N/A
- ABP N/A
- Revenue
- PHIO N/A
- ABP $183,000.00
- Revenue This Year
- PHIO N/A
- ABP N/A
- Revenue Next Year
- PHIO N/A
- ABP N/A
- P/E Ratio
- PHIO N/A
- ABP N/A
- Revenue Growth
- PHIO N/A
- ABP 88.66
- 52 Week Low
- PHIO $0.97
- ABP $0.15
- 52 Week High
- PHIO $9.79
- ABP $11.19
- Technical
- Relative Strength Index (RSI)
- PHIO 56.49
- ABP N/A
- Support Level
- PHIO $2.31
- ABP N/A
- Resistance Level
- PHIO $2.45
- ABP N/A
- Average True Range (ATR)
- PHIO 0.13
- ABP 0.00
- MACD
- PHIO 0.00
- ABP 0.00
- Stochastic Oscillator
- PHIO 64.52
- ABP 0.00
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
About ABP Abpro Holdings Inc Common Stock
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.